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A B S T R A C T
Aim. – Type 2 diabetes (T2D) alters glucagon, glucagon-like peptide (GLP)-1, glucose-dependent
insulinotropic polypeptide (GIP) and hepatic energy metabolism, yet the possible relationships remain
unclear.
Methods. – In this observational study, lean insulin-sensitive control subjects (BMI: 23.2  1.5 kg/m2),
age-matched insulin-resistant obese subjects (BMI: 34.3  1.7 kg/m2) and similarly obese elderly T2D
patients (BMI: 32.0  2.4 kg/m2) underwent mixed-meal tolerance tests (MMTTs), and assessment of hepatic
gATP, inorganic phosphate (Pi) and lipids using
31P/1H magnetic resonance spectroscopy. Meal-induced
secretion of glucagon and incretins was calculated from incremental areas under the concentration–time
curves (iAUCs). Peripheral and adipose tissue insulin sensitivity were assessed from time courses of
circulating glucose, insulin and free fatty acids.
Results. – MMTT-derived peripheral insulin sensitivity was lowest in T2D patients (P < 0.001), while
glucagon concentrations were comparable across all three groups. At 260 min, GLP-1 was lower in T2D
patients than in controls, whereas GIP was lowest in obese individuals. Fasting glucagon concentrations
correlated positively with fasting (r = 0.60) and postprandial hepatocellular lipid levels (160 min:
r = 0.51, 240 min: r = 0.59), and negatively with adipose tissue insulin sensitivity (r = 0.73). Higher
meal-induced glucagon release (iAUC0–260 min) correlated with lower fasting (r = 0.62) and
postprandial Pi levels (160 min: r = 0.43, 240 min: r = 0.42; all P < 0.05). Higher meal-induced
release of GIP (iAUC0–260 min) correlated positively with fasting (r = 0.54) and postprandial serum
triglyceride concentrations (iAUC0–260 min, r = 0.54; all P < 0.01).
Conclusion. – Correlations between fasting glucagon and hepatic lipids and between meal-induced
glucagon and hepatic Pi suggest a role for glucagon in hepatic energy metabolism.
C 2018 Elsevier Masson SAS. All rights reserved.
Abbreviations: ANOVA, analysis of variance; ANCOVA, analysis of covariance; BMI, body mass index; AUC, area under the concentration–time curve; CON, lean insulin-
sensitive controls; ELISA, enzyme-linked immunosorbent assay; GIP, glucose-dependent insulinogenic polypeptide; GLP-1, glucagon-like peptide-1; HCL, hepatocellular
lipid; iAUC, incremental area under the concentration–time curve; MMTT, mixed-meal tolerance test; MRS, magnetic resonance spectroscopy; NAFLD, non-alcoholic fatty
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Introduction
In obese individuals with non-alcoholic fatty liver disease
(NAFLD), postprandial adaptation of hepatic energy metabolism to
higher substrate flux is enhanced, leading to hepatic oxidative
stress, which may predispose to non-alcoholic steatohepatitis
(NASH) [1,2]. Patients with type 2 diabetes (T2D) also frequently
present with increased hepatocellular lipid (HCL) content, which is
associated with hepatic insulin resistance, impaired energy
metabolism and oxidative stress [3]. Of note, the ability of
glucagon to stimulate hepatic gluconeogenesis is increased in
progressive NAFLD (or, specifically, NASH) [4]. Glucagon-like
peptide (GLP)-1 and glucose-dependent insulinogenic polypeptide
(GIP) may also contribute to hepatic energy metabolism by
modulating postprandial insulin and glucagon secretion. However,
the role of glucagon and incretins in the control of postprandial
hepatic energy metabolism in humans is as yet unclear.
Thus, the present study aimed to test the hypothesis that
glucagon concentrations are inversely related to hepatic energy
metabolism, and to assess the effects of fasting and mixed-meal
tolerance test (MMTT)-induced changes to plasma glucagon
concentrations on hepatic energy metabolism and tissue-specific
insulin sensitivity in lean insulin-sensitive control subjects (CON),
age-matched insulin-resistant but glucose-tolerant obese individ-
uals (OBE) and elderly obese patients with T2D. The secondary aim
of the study was to additionally assess these associations in
relation to GLP-1 and GIP.
Methods
The study design and population have already been described in
detail elsewhere [1]. The trial was registered at https://
clinicaltrials.gov (NCT01229059). Briefly, between March
2012 and October 2013, 10 CON, 10 age-matched OBE and
10 elderly obese patients with T2D (Table S1 (see supplementary
materials associated with this article online) underwent a
standardized liquid MMTT (2728 kJ, 83.6 g of carbohydrates,
23.2 g of protein, 24.0 g of fat), with blood samples taken under
fasting and postprandial conditions. Composition of the MMTT was
identical to that of a previous study, which demonstrated higher
post-meal hepatic de-novo lipogenesis in insulin-resistant than in
insulin-sensitive individuals [5]. 31P/1H magnetic resonance
spectroscopy (MRS) was performed before and at 160 min and
240 min after meal ingestion.
For 3 days prior to the clinical visit, participants adhered to a
balanced isocaloric diet and refrained from physical activity and
alcohol consumption. Also, patients with T2D stopped their
glucose-lowering or lipid-lowering medication for at least 3 days
prior to the visits. In addition, all subjects gave their written
informed consent to participate in the study, which was approved
by the local ethics board [1].
Measurements of circulating glucose, C-peptide, insulin and
triglyceride concentrations, as well as MRS-based quantification of
HCL, gamma-adenosine triphosphate (gATP) and inorganic phos-
phate (Pi) have been previously described [1]. Plasma glucagon was
assessed using radioimmunoassay (EMD Millipore, Saint Charles,
MO, USA) before and 15, 30, 60, 90, 120, 180 and 260 min after
meal ingestion. Using identical time points, plasma GIP was
measured using enzyme-linked immunosorbent assay (ELISA) for
human total GIP (EMD Millipore). Measurements of the bioactive
form of plasma GLP-1 (7–36) were performed before and 15, 30, 60,
90 and 260 min after meal ingestion, using high-sensitivity GLP-1
ELISA (Epitope Diagnostics Inc., San Diego, CA, USA).
Areas under the concentration–time curves (AUCs) for gluca-
gon, GLP-1 and GIP were calculated, using the trapezoidal method
and corrected for fasting (basal) incretin release, to yield the
incremental AUC (iAUC). Peripheral insulin sensitivity was
calculated by applying the oral glucose tolerance test (OGTT)-
based formula for oral glucose insulin sensitivity (OGIS) index to
the MMTT [6]. Adipose tissue insulin sensitivity was derived from
mathematical modelling of free fatty acid and insulin concen-
trations [7].
Non-normally distributed variables (serum triglycerides, glu-
cagon, HCL, GLP-1, GIP) were 1n-transformed to improve
normality. Comparisons between groups at every time point of
the MMTT were performed using covariance pattern analysis,
which considers dependency between observations at different
time points on specific subjects, with Bonferroni-based Dunn’s test
to correct for multiple comparisons. Analysis of variance (ANOVA)
was applied to test for differences in the AUCs between groups,
with Bonferroni correction for multiple comparisons [1]. Also, by
applying the Wilcoxon signed-rank test to the iAUCs of glucagon,
GIP and GLP-1, it was possible to test whether concentrations of
these hormones significantly increased during the MMTT. Partial
Pearson correlation coefficients (r) and corresponding P values
were calculated based on the entire study sample, and adjusted for
group effect, age, gender and body mass index (BMI). Interactions
between groups were analyzed by two-way analysis of covariance
(ANCOVA).
Results
MMTT-derived peripheral insulin sensitivity (OGIS) was
lowest in T2D patients and highest in CON, whereas adipose
tissue insulin sensitivity was comparable between groups (Table
S1). In addition, after MMTT ingestion, GIP and GLP-1 concen-
trations increased in all groups, while glucagon levels increased
only in patients with T2D, from 90.7  1.5 pg/mL to a maximum of
111.1  1.5 pg/mL at 30 min (all P < 0.004). When comparing
hormone levels among the CON, OBE and T2D at a single time point
during the MMTT, glucagon levels did not differ across groups (Fig.
S1A, B (see supplementary materials associated with this article
online), whereas GLP-1 levels at fasting and at 260 min were lower in
T2D compared with CON (Fig. S1G, H (see supplementary materials
associated with this article online), and GIP260 min was lower in OBE
than in either CON or T2D groups (Fig. S1D, E (see supplementary
materials associated with this article online). In addition, AUCs for
glucagon, GLP-1 and GIP were comparable across all three groups
(Fig. S1C, F (see supplementary materials associated with this article
online).
GLP-1 iAUC0–260 min (r = 0.43, P = 0.044; Fig. 1A) and fasting
glucagon (r = 0.73, P < 0.001) (Fig. 1B) were inversely correlated
with adipose tissue insulin sensitivity. Higher fasting glucagon, but
not glucagon iAUC0–260 min, correlated with higher HCL at fasting,
at 160 min and at 240 min (Fig. 1C, Table S2 (see supplementary
materials associated with this article online). Also, glucagon
iAUC0–260 min did not correlate with the change in HCL (D HCL160
min fasting: r = 0.19, P = 0.354 and D HCL240 min fasting: r = 0.17,
P = 0.415). Higher glucagon iAUC0–260 min was correlated with
lower Pi at fasting, at 160 min and at 240 min, but did not correlate
with gATP (Fig. 1D, Table S2). Exclusion of the outlier in the CON
group did not affect the results of our correlation analyses.
GIP iAUC0–260 min correlated with fasting serum triglycerides
and the serum triglyceride iAUC0–260 min (r = 0.54, P = 0.005 and
r = 0.54, P = 0.005, respectively; Fig. 1E,F), whereas there was no
correlation between fasting GIP and either fasting serum
triglycerides (r = 0.18, P = 0.379) or serum triglyceride iAUC0-260
min (r = 0.11, P = 0.610). Also, it is worth noting that all correlations
were independent of age, gender and BMI, and there were no
significant interactions between CON, OBE and T2D patients.
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Discussion
The present study results indicate that:
 higher meal-induced glucagon secretion correlates with lower
fasting and postprandial hepatic phosphate concentrations;
 higher fasting glucagon concentrations correlate with lower
adipose tissue insulin sensitivity, but also with higher fasting
and postprandial HCL;
 postprandial GIP secretion directly correlates with fasting and
postprandial serum triglyceride concentrations.
Glucagon is known to inhibit glycolysis [8]. However, lower
glycolytic ATP production is partially balanced by a glucagon-
induced increase in mitochondrial oxidative phosphorylation [8]. In
mice, the stimulatory effect of glucagon on hepatic mitochondrial
oxidation has been shown to be mediated by calcium signalling
through inositol 1,4,5-trisphosphate receptor-1 [9]. Calcium has, in
addition, long been known to be essential for glucagon-induced
stimulation of gluconeogenesis [10]. Moreover, calcium stimulation
of the murine mitochondrial ATP-Mg/Pi small calcium-binding
mitochondrial carrier (SCaMC)-3 has been described to couple
[(Fig._1)TD$FIG]
Fig. 1. Correlation analyses of glucagon, glucagon-like peptide (GLP)-1 and glucose-dependent insulinogenic polypeptide (GIP) with adipose tissue insulin sensitivity,
hepatocellular lipid content (HLC), hepatic inorganic phosphate (Pi) and triglyceride concentrations. Partial Pearson correlation coefficients (r) and corresponding P values
were adjusted for group effect, age, gender and body mass index (BMI). Fasting glucagon, HCL at 240 min and fasting serum triglycerides were ln-transformed prior to analysis
to reach normality. The x (B, C) and y (C, E) axes show a natural logarithmic scale. Grey open triangles indicate young lean insulin-sensitive controls (CON), grey solid circles
indicate obese insulin-resistant subjects (OBE) and black squares are patients with type 2 diabetes (T2D). (A) Data only available for 27 participants: 9 CON; 9 OBE; and 9 T2D
patients. iAUC: incremental area under the concentration curve.
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respiration and oxidative phosphorylation in response to glucagon
[8]. The inverse correlation between glucagon secretion and hepatic
Pi concentrations observed in the present study suggests that
glucagon might be decreasing mitochondrial oxidative phosphor-
ylation instead of mitochondrial coupling.
The reduced adipose tissue insulin sensitivity under conditions
of higher fasting glucagon concentrations might also have
contributed to higher levels of circulating triglycerides and free
fatty acids by augmented lipid flux to the liver [11], an idea
supported by the observed direct correlation between fasting
glucagon and HCL. Elevated plasma free fatty acid concentrations
have been also shown to cause hepatic insulin resistance and to
stimulate gluconeogenesis [11], which might lower hepatic ATP
and Pi concentrations.
Of note, although glucagon increased from 90.7 1.5 pg/mL to
only 111.1 1.5 pg/mL in our T2D patients, it has previously been
shown that even minor changes in glucagon can significantly affect
hepatic glucose metabolism and, thus, are of physiological relevance
[12]. Furthermore, the comparable glucagon concentrations between
those with and without T2D in our study were somewhat unexpected,
as inappropriate hyperglucagonaemia has been described as a common
feature of T2D [13]. However, such similar glucagon concentrations
have been reported previously [14] and could be due to the rather short
duration (5.7 years) of known diabetes [1] and relatively good
glucometabolic control of the T2D patients in our study (Table S1).
Although glucose concentrations were higher in both OBE and
T2D groups compared with CON after MMTT, insulin secretion was
increased only in the OBE while remaining comparable between
the T2D and CON [1], most likely due to impaired incretin secretion
and/or efficacy in T2D. While fasting GIP concentrations have
previously been shown to have links with both fasting and meal-
stimulated serum triglycerides in individuals with normal/
impaired glucose tolerance or T2D [15], the present results
indicate that meal-stimulated rather than fasting GIP secretion
influences circulating triglycerides.
The strengths of our present study are, first, the inclusion of
insulin-sensitive subjects, glucose-tolerant yet insulin-resistant
individuals and T2D patients, thereby allowing direct comparisons
of these metabolic states. Second, hepatic energy metabolism was
monitored non-invasively by absolute quantification of hepatic
ATP concentrations using in-vivo 31P MRS, which reflects
unidirectional flux through hepatic ATP synthase [3]. Third,
covariance pattern analyses, which fully explore time effects,
were applied for comparisons of incretin and glucagon responses
to MMTT between groups.
On the other hand, one study limitation is the small number of
participants in each of our three heterogeneous groups. It should
be noted that a sample size of 30 ensures that an association
between adipose tissue insulin sensitivity, HCL, Pi, serum
triglyceride and hormone concentrations can be detected with a
power of 80% if the corresponding partial correlation, adjusted for
up to four potential confounders, is  0.52. Thus, our present
results require confirmation in studies with larger sample sizes
and more homogeneous groups of OBE and T2D patients. Another
limitation is that hepatic ATP concentrations represent only one
feature of hepatic energy metabolism [4].
In conclusion, meal-stimulated glucagon and GIP secretion may
play a role in postprandial regulation of hepatic energy metabolism
and circulating triglycerides. Further research is now warranted to
determine the molecular mechanisms by which glucagon and
incretins act on hepatic energy metabolism and NAFLD.
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